Claims
- 1. A process for treating non-malignant proliferative skin diseases which comprises administering to the afflicted human or animal, a composition containing as an active component at least one compound selected from the group consisting of methyl glyoxal bis-(guanyl hydrazone) and 1,1'-methylethanediylidinedinitrilo)-bis-(3-aminoguanidine), said compound being in association with a pharmaceutical carrier wherein the concentration of said active component is effective to alleviate a proliferative skin disease.
- 2. A process in accordance with claim 1 wherein said active component is methyl glyoxal bis-(guanyl hydrazone).
- 3. A process in accordance with claim 1 wherein said active component is 1,1'-methylethanediylidinedinitrilo-bis-(3-aminoguanidine).
- 4. A process for treating non-malignant proliferative skin diseases which comprises administering to the afflicted human or animal, a composition containing as an active component at least one compound selected from the group consisting of methyl glyoxal bis(guanyl hydrazone) and 1,1'-methylethanediylidinedinitrilo)-bis-(3-aminoguanidine), and a minor amount of a glucocorticoid, said compounds being in association with a pharmaceutical carrier wherein the concentration of said active component is effective to alleviate a proliferative skin disease.
- 5. A process for treating non-malignant proliferative skin diseases which comprises administering to the afflicted human or animal, a composition containing as an active component at least one of the compounds selected from the groups consisting of;
- I A compound of the formula ##STR6## wherein R.sub.1 is H or methyl; R.sub.2 is H or phenyl; R.sub.3 is propyl, isopropyl or phenyl; R.sub.4 is H, bromine, methylthio, or benzylthio; X is oxygen or methylene;
- II a compound of the formula ##STR7## wherein R.sub.1 and R.sub.2 are hydrogen or hydroxyl; Y is hydrogen, or alkali metal; Z is hydrogen, benzylthio, thiol, halogen, alkylthio wherein alkyl is from 1 to 8 carbon atoms, inclusive, and hydroxy; R.sub.4 is hydrogen, ##STR8## wherein R.sub.5 is phenyl, benzyl or alkyl of 1 to 8 carbon atoms; III A compound of the formula ##STR9## wherein R.sub.1 is --CONH.sub.2, --C(NH)NH.sub.2, --C(NH)NHOH, --CN, or --COOCH.sub.3 ; R.sub.1 and R.sub.2 are hydrogen or hydroxy; Y is hydrogen or alkali metal;
- IV a compound selected from the group consisting of compounds characterized by the formula ##STR10## wherein R is halogen, hydrogen, lower alkyl and lower alkoxy; R.sub.2, R.sub.3 and R.sub.4 taken independently of each other are hydrogen, lower alkoxy or hydroxy-lower alkoxy and provided that R.sub.2, R.sub.3 and R.sub.4 taken independently of each other represent at least one oxygenated substitutent; or R, R.sub.2, R.sub.3 and R.sub.4 taken as an adjacent pair is methylenedioxy and the optical antipodes thereof, and
- V Prostaglandin compounds of the D-type (PGD) selected from the group consisting of PGE.sub.1, PGE.sub.2, PGE.sub.3 or the alkyl ester thereof containing from 1 to 8 carbon atoms inclusive, or 13, 14-dihydro PGE.sub.1 or the alkyl esters thereof containing from 1 to 8 carbon atoms inclusive, and PGD.sub.2 and the alkyl esters thereof containing from 1 to 8 carbon atoms inclusive, and at least one compound selected from the group consisting of methyl glyoxal bis-(guanyl hydrazone) and 1,1'-methylethanediylidinedinitrilo-bis-(3-aminoguanidine), said compounds being in association with a pharmaceutical carrier wherein the concentration of said active component is effective to alleviate a proliferative skin disease.
- 6. A process in accordance with claim 5 wherein said compound is methyl glyoxal bis-(guanyl hydrazone).
- 7. A process in accordance with claim 5 wherein said active component is 1,1'-methylethanediylidinedinitrilo-bis-(3-aminoguanidine).
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of United States Ser. No. 734,152, filed Oct. 20, 1976, now abandoned.
US Referenced Citations (3)
Non-Patent Literature Citations (4)
Entry |
Cancer Research, 34, 886-892, (1974). |
Biochimica et Biophysica Acta, 473, (1978), 241-293. |
Handbook of Non-Prescription Drugs, 5th ed., 332, (1977). |
Physicians Desk Reference, 26th ed., pp. 809-811, (1972). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
734152 |
Oct 1976 |
|